Onconetix Balance Sheet Health
Financial Health criteria checks 2/6
Onconetix has a total shareholder equity of $1.4M and total debt of $9.7M, which brings its debt-to-equity ratio to 693.3%. Its total assets and total liabilities are $87.5M and $86.1M respectively.
Key information
693.3%
Debt to equity ratio
US$9.74m
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.55m |
| Equity | US$1.40m |
| Total liabilities | US$86.11m |
| Total assets | US$87.52m |
Recent financial health updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17Financial Position Analysis
Short Term Liabilities: ONCO's short term assets ($5.8M) do not cover its short term liabilities ($17.2M).
Long Term Liabilities: ONCO's short term assets ($5.8M) do not cover its long term liabilities ($68.9M).
Debt to Equity History and Analysis
Debt Level: ONCO's net debt to equity ratio (369%) is considered high.
Reducing Debt: Insufficient data to determine if ONCO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ONCO is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.